500 mg PO/IV once daily for 10-14 days or 750 mg PO/IV once daily for 5 days Limitations-of-use: Reserve fluoroquinolones for patients who do not have other available treatment options for acute sinusitis Indicated for treatment and prophylaxis of plague, including pneumonic and septicemic plague, caused by Yersinia pestis in adults and pediatric patients, aged 6 months or older 500 mg PO/IV once daily for 10-14 days Nausea (7%) Headache (6%) Diarrhea (5%) Insomnia (4%) Constipation (3%) Dizziness (3%) Dyspepsia (2%) Rash (2%) Vomiting (2%) Chest pain (1%) Dyspnea (1%) Edema (1%) Fatigue (1%) Injection-site reaction (1%) Moniliasis (1%) Pain (1%) Pruritus (1%) Vaginitis (1%) Cardiac: Cardiac arrest, palpitation, ventricular tachycardia, arrhythmia Nervous system: Tremor, convulsions, paresthesia, vertigo, hypertonia, hyperkinesias, abnormal gait, somnolence, syncope Metabolic: Hypoglycemia, hyperglycemia, hyperkalemia Blood/lymphatic system: Anemia, thrombocytopenia, granulocytopenia Musculoskeletal/connective tissue: Arthralgia, tendonitis, myalgia, skeletal pain Gastrointestinal (GI): Gastritis, stomatitis, pancreatitis, esophagitis, gastroenteritis, glossitis, pseudomembranous/C difficile colitis Hepatobiliary: Abnormal hepatic function, increased hepatic enzymes, increased alkaline phosphatase Psychiatric: Anxiety, agitation, confusion, depression, hallucinations, nightmares, sleep disorder, anorexia, abnormal dreaming Other: Immune hypersensitivity reaction, acute renal failure, urticaria, phlebitis, epistaxis Cardiac: Prolonged QT interval, torsades de pointes, tachycardia Musculoskeletal/connective tissue: Tendon rupture, muscle injury, rhabdomyolysis Skin/subcutaneous tissue: Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme, photosensitivity/phototoxicity, leukocytoclastic vasculitis Renal and urinary disorders: Interstitial nephritis Vascular disorders: Vasodilation Blood/lymphatic system: Pancytopenia, aplastic anemia, leukopenia, hemolytic anemia, eosinophilia Hepatobiliary: Hepatic failure, hepatitis, jaundice Psychiatric: Psychosis, paranoia, suicidal ideation, isolated reports of suicide attempts Nervous system: Exacerbation of myasthenia gravis, anosmia, ageusia, parosmia, dysgeusia, peripheral neuropathy, abnormal electroencephalogram (EEG), dysphonia, isolated reports of encephalopathy, pseudotumor cerebri Central nervous system effects (hallucinations, anxiety, depression, insomnia, severe headaches, and confusion) Respiratory, thoracic and mediastinal disorders: Isolated reports of allergic pneumonitis Immune system disorders: Hypersensitivity reactions, sometimes fatal including: anaphylactic/anaphylactoid reactions, anaphylactic shock, angioneurotic edema, serum sickness Eye disorders: Uveitis, vision disturbance (including diplopia), visual acuity reduced, vision blurred, scotoma Otologic: Hypoacusis, tinnitus General disorders and administration site conditions: Multiorgan failure, pyrexia May exacerbate muscle weakness in patients with myasthenia gravis; fluoroquinolones should be avoided in patients with known history of myasthenia gravis Because the risk of these serious side effects generally outweighs the benefits for patients with acute bacterial sinusitis, acute exacerbation of chronic bronchitis, and uncomplicated UTIs, that fluoroquinolones should be reserved for use in patients with these conditions who have no alternative treatment options For some serious bacterial infections, including anthrax, plague, and bacterial pneumonia among others, the benefits of fluoroquinolones outweigh the risks and it is appropriate for them to remain available as a therapeutic option Anaphylactic reactions and allergic skin reactions, serious, occasionally fatal, may occur after first dose Use caution in hematologic and renal toxicities Hepatotoxicity reported with therapy Peripheral neuropathy: Sensory or sensorimotor axonal polyneuropathy affecting small and/or large axons resulting in paresthesias, hypoesthesias, dysesthesias, and weakness reported; peripheral neuropathy may occur rapidly after initiating and may potentially become permanent Commonly seen adverse reactions include tendinitis, tendon rupture, arthralgia, myalgia, peripheral neuropathy, and central nervous system effects (hallucinations, anxiety, depression, insomnia, severe headaches, and confusion); these reactions can occur within hours to weeks after starting therapy, including in patients of any age or without pre-existing risk factors; discontinue therapy immediately at first signs or symptoms of any serious adverse reaction; in addition, avoid use of fluoroquinolones, in patients who have experienced any serious adverse reactions associated with fluoroquinolones Risk of developing fluoroquinolone-associated tendinitis and tendon rupture is increased in patients over 60 years of age, in patients taking corticosteroid drugs, and in patients with kidney, heart or lung transplants; other factors that may independently increase risk of tendon rupture include strenuous physical activity, renal failure, and previous tendon disorders such as rheumatoid arthritis (see Black Box Warnings) Excessive sunlight may result in moderate-to-severe phototoxicity Fatal hypoglycemia reported in elderly patients with or without diabetes; prompt treatment when symptoms are present is essential May cause C difficile-associated colitis Prolonged use may result in fungal or bacterial superinfection Prolongation of QT interval and isolated cases of torsades de pointes; avoid use in patients with known QT prolongation, those with hypokalemia, and those taking other QT-prolonging drugs May produce false-positive urine opiate screens In prolonged therapy, perform periodic evaluations of organ system function (eg, renal, hepatic, hematopoietic); adjust dosage in renal impairment; superinfections may occur with prolonged or repeated antibiotic therapy Pediatric patients may experience increased incidence of musculoskeletal disorders (eg, arthralgia, arthritis, tendinopathy, gait abnormality) Acute onset of retinal detachment increased 4.5-fold with oral fluoroquinolones in a single case-controlled study - JAMA 2012;307(13):1414-1419; another study disputes these findings (relative risk, 1.29) - JAMA 2013;310(20):2184-2190 Clostridium difficile-associated diarrhea (CDAD) has been reported; if CDAD suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued; appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C. difficile, and surgical evaluation should be instituted as clinically indicated Prescribing antibiotics in absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to patient and increases risk of development of drug-resistant bacteria L-stereoisomer of parent compound ofloxacin; D-isomer form is inactive Inhibits DNA gyrase activity, which in turn promotes breakage of DNA strands Good monotherapy with extended coverage against Pseudomonas spp, as well as excellent activity against pneumococcus Additive: Linezolid Y-site: Amikacin, aminophylline, ampicillin, bivalirudin, caffeine, cefotaxime, cimetidine, clindamycin, dexamethasone, dexmedetomidine, dobutamine, dopamine, epinephrine, fenoldopam, fentanyl, gentamicin, lactated hetastarch, insulin (at 1 U/m L 5 mg/m L levofloxacin), isoproterenol, lidocaine, linezolid, lorazepam, metoclopramide, oxacillin, pancuronium, penicillin G sodium, phenobarbital, phenylephrine, sodium bicarbonate, vancomycin Premixed: No further preparation needed Single-use vials: Dilute in 50-100 m L D5W or NS or D5/NS solution for injection to 5 mg/m L; alternative solutions include sodium lactate, Plasma-Lyte, D5/lactated Ringer, D5/NS and potassium chloride Reconstituted solution should be clear, slightly yellow, and free of particulate matter Reconstituted drug is stable for 72 hours at room temperature, 14 days when refrigerated in plastic containers, and 6 months when frozen Thaw at room temperature or in refrigerator only Give by IV infusion only, not bolus; rapid or bolus administration has been associated with hypotension and must be avoided Infuse 250-500 mg over 60 minutes or 750 mg over 90 minutes Avoid using IV line with solution containing multivalent cations (ie, magnesium, calcium) Compatible with potassium additives The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information. cialis pills for sale Levofloxacin is a prescription drug that comes as an oral tablet, oral solution, and ophthalmic solution (eye drop). It also comes in an intravenous (IV) form that’s only given by a healthcare provider. Levofloxacin oral tablet is available as a generic drug only. Generic drugs usually cost less than brand-name drugs. Levofloxacin oral tablet is used to treat bacterial infections in adults. These infections include: Levofloxacin may be used as part of a combination therapy. This means you may need to take it with other medications. Ciprofloxacin medication Viagra 1998 Adult Dosing FAQ about this section. Dosage forms TAB 250 mg, 500 mg, 750 mg. Dosage Forms Discontinued in US. IV, oral solution not avail. as brand; see. buy clomid walmart The usual dose is 250-750 mg given once daily for 3-14 days depending on the. Levaquin is not recommended for use in pregnant women since Levaquin. Detailed dosage guidelines and administration information for Levaquin. These recommendations apply to patients with creatinine clearance ≥ 50 mL/minute. Growing resistance in some bacteria that commonly cause community-acquired pneumonia (CAP) in children has increased the need for alternative antibiotics. Food and Drug Administration for use in children, but historical data on fluoroquinolones in children suggest an adverse event rate similar to that found in adults. Because levofloxacin has a broad spectrum of activity against bacterial and atypical pathogens and because it has an acceptable safety profile in adults, Bradley and colleagues studied the safety and effectiveness of levofloxacin to treat CAP in children. This randomized, multicenter, open-label study evaluated children six months to 16 years of age in seven countries, including the United States. Children were eligible to participate if they had a clinical diagnosis of CAP based on positive radiographic findings and the presence of two or more clinical findings of pneumonia (e.g., fever, dyspnea, cough, chest pain, abnormal white blood cell count, physical signs on examination). Children in outpatient and inpatient settings were included. Children were excluded if they received systemic antibiotics for more than 24 hours immediately before enrollment, if they required antibiotics other than the study drugs, or if they had an infection suspected to be resistant to the study drugs. The NICE British National Formulary (BNF) and British National Formulary for Children (BNFc) sites are only available to users in the UK, Crown Dependencies and British Overseas Territories. If you believe you are seeing this page in error please contact us. What is the recommended dosage of levaquin LEVAQUIN Dosage & Rx Info Uses, Side Effects - MPR, Levaquin levofloxacin Antibiotic Side Effects, Uses & Dosage Cialis price at walmart Lasix oral dosage Sildenafil effervescent Oct 17, 2008. Dose & Duration The recommended dose for levofloxacin is 500mg i.v./oral once daily for 10-14 days normal course of therapy or 750mg. Levofloxacin for acute bacterial sinusitis Therapeutics Initiative Levaquin Dosage Guide - Levaquin, Levofloxacin Systemic levofloxacin dosing, indications. Learn about Levaquin Levofloxacin may treat, uses, dosage, side effects, drug. It is recommended that Levofloxacin Oral Solution be taken 1 hour before or 2. buy viagra asda Nov 18, 2014. Levaquin is the brand name for levofloxacin, a prescription antibiotic used to treat a variety of bacterial infections. Dosage in Adult Patients with Normal Renal Function 2.1. 5/2008. therapy with an anti-pseudomonal β-lactam is recommended see Clinical Studies 14.1.